Assessing Humoral Immuno-Inflammatory Pathways Associated with Respiratory Failure in COVID-19 Patients
Abstract
:1. Introduction
2. Materials and Methods
- (1)
- A reliable diagnosis of SARS-CoV-2 infection obtained by RT-PCR molecular swab testing.
- (2)
- No history of pharmacological treatments responsible for alterations in the leukocyte count and/or CRP upon admission.
- (3)
- No current or past history of conditions responsible for alterations in the leukocyte count and/or CRP.
- (4)
- Availability of at least three blood tests and blood gas analyses during hospitalization, and a hospitalization period not less than 48 h.
Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
ANC | absolute neutrophil count |
C-PAP | continuous-positive air pressure |
CRP | C-reactive protein |
HFCN | high flow nasal cannula |
ICU | Intensive Care Unit |
LYMPH | lymphocytes |
NIMV | non-invasive mechanic ventilation |
NIV | non-invasive ventilation |
NLR | neutrophil-to-lymphocyte ratio |
P/F | PaO2/FiO2 ratio |
CAP | Community acquired pneumonia |
CKD | chronic kidney disease |
COPD | chronic obstructive pulmonary disease |
CV disease | cardio-vascular disease |
V/Q | ventilation/perfusion |
References
- da Rosa Mesquita, R.; Francelino Silva, L.C., Jr.; Santos Santana, F.M.; Farias de Oliveira, T.; Campos Alcântara, R.; Monteiro Arnozo, G.; da Silva Filho, E.R.; Galdino dos Santos, A.G.; Oliveira da Cunha, E.J.; Salgueiro de Aquino, S.H.; et al. Clinical manifestations of COVID-19 in the general population: Systematic review. Wien. Klin. Wochenschr. 2021, 133, 377–382. [Google Scholar] [CrossRef]
- Zhu, J.; Ji, P.; Pang, J.; Zhong, Z.; Li, H.; He, C.; Zhang, J.; Zhao, C. Clinical characteristics of 3062 COVID-19 patients: A meta-analysis. J. Med. Virol. 2020, 92, 1902–1914. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Caramaschi, S.; Kapp, M.E.; Miller, S.E.; Eisenberg, R.; Johnson, J.; Epperly, G.; Maiorana, A.; Silvestri, G.; Giannico, G.A. Histopathological findings and clinicopathologic correlation in COVID-19: A systematic Review. Mod. Pathol. 2021, 34, 1614–1633. [Google Scholar] [CrossRef]
- The ARDS Definition Task Force. Acute respiratory distress syndrome. JAMA 2012, 307, 2526–2533. [Google Scholar] [CrossRef]
- Gattinoni, L.; Chiumello, D.; Caironi, P.; Busana, M.; Romitti, F.; Brazzi, L.; Camporota, L. COVID-19 pneumonia: Different respiratory treatments for different phenotypes? Intensive Care Med. 2020, 46, 1099–1102. [Google Scholar] [CrossRef] [Green Version]
- Hu, B.; Huang, S.; Yin, L. The cytokine storm and COVID-19. J. Med. Virol. 2021, 93, 250–256. [Google Scholar] [CrossRef] [PubMed]
- Vaninov, N. In the eye of the COVID-19 cytokine storm. Nat. Rev. Immunol. 2020, 20, 277. [Google Scholar] [CrossRef]
- Yang, L.; Xie, X.; Tu, Z.; Fu, J.; Xu, D.; Zhou, Y. The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduct. Target. Ther. 2021, 6, 255. [Google Scholar] [CrossRef]
- Xu, Z.; Shi, L.; Wang, Y.; Zhang, J.; Huang, L.; Zhang, C.; Liu, S.; Zhao, P.; Liu, H.; Zhu, L.; et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 2020, 8, 420–422. [Google Scholar] [CrossRef]
- Ou, M.; Zhu, J.; Ji, P.; Li, H.; Zhong, Z.; Li, B.; Pang, J.; Zhang, J.; Zheng, X. Risk factors of severe cases with COVID-19: A meta-analysis. Epidemiol. Infect. 2020, 148, e175. [Google Scholar] [CrossRef]
- Wolff, D.; Nee, S.; Hickey, N.S.; Marschollek, M. Risk factors for Covid-19 severity and fatality: A structured literature review. Infection 2021, 49, 15–28. [Google Scholar] [CrossRef]
- Clyne, B.; Olshaker, J.S. The C-reactive protein. J. Emerg. Med. 1999, 17, 1019–1025. [Google Scholar] [CrossRef]
- Zahorec, R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives. Bratisl. Lek. Listy 2021, 122, 474–488. [Google Scholar] [CrossRef]
- Regolo, M.; Vaccaro, M.; Sorce, A.; Stancanelli, B.; Colaci, M.; Natoli, G.; Russo, M.; Alessandria, I.; Motta, M.; Santangelo, N.; et al. Neutrophil-to-Lymphocyte Ratio (NLR) Is a Promising Predictor of Mortality and Admission to Intensive Care Unit of COVID-19 Patients. J. Clin. Med. 2022, 11, 2235. [Google Scholar] [CrossRef]
- Sinatti, G.; Santini, S.J.; Tarantino, G.; Picchi, G.; Cosimini, B.; Ranfone, F.; Casano, N.; Zingaropoli, M.A.; Iapadre, N.; Bianconi, S.; et al. PaO2/FiO2 ratio forecasts COVID-19 patients’ outcome regardless of age: A cross-sectional, monocentric study. Intern. Emerg. Med. 2022, 17, 665–673. [Google Scholar] [CrossRef] [PubMed]
- Marini, J.J.; Gattinoni, L. Management of COVID-19 respiratory distress. JAMA 2020, 323, 2329–2330. [Google Scholar] [CrossRef] [Green Version]
- Zanoli, L.; Briet, M.; Empana, J.P.; Cunha, P.G.; Mäki-Petäjä, K.M.; Protogerou, A.D.; Tedgui, A.; Touyz, R.M.; Schiffrin, E.L.; Spronck, B.; et al. Vascular consequences of inflammation: A position statement from the ESH Working Group on Vascular Structure and Function and the ARTERY Society. J. Hypertens. 2020, 38, 1682–1698. [Google Scholar] [CrossRef]
- Zanoli, L.; Gaudio, A.; Mikhailidis, D.P.; Katsiki, N.; Castellino, N.; Lo Cicero, L.; Geraci, G.; Sessa, C.; Fiorito, L.; Marino, F.; et al. Vascular Dysfunction of COVID-19 Is Partially Reverted in the Long-Term. Circ. Res. 2022, 130, 1276–1285. [Google Scholar] [CrossRef]
- Pepys, M.B.; Hirschfield, G.M. C-reactive protein: A critical update. J. Clin. Investig. 2003, 111, 1805–1812, Erratum in J. Clin. Investig. 2003, 112, 299. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gustine, J.N.; Jones, D. Immunopathology of Hyperinflammation in COVID-19. Am. J. Pathol. 2021, 191, 4–17. [Google Scholar] [CrossRef] [PubMed]
- Haverkate, F.; Thompson, S.G.; Pyke, S.D.; Gallimore, J.R.; Pepys, M.B. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997, 349, 462–466. [Google Scholar] [CrossRef] [PubMed]
- Ridker, P.M.; Rifai, N.; Rose, L.; Buring, J.E.; Cook, N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 2002, 347, 1557–1565. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sproston, N.R.; Ashworth, J.J. Role of C-Reactive Protein at Sites of Inflammation and Infection. Front. Immunol. 2018, 9, 754. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mold, C.; Gewurz, H.; Du Clos, T.W. Regulation of complement activation by C-reactive protein. Immunopharmacology 1999, 42, 23–30. [Google Scholar] [CrossRef] [PubMed]
- Buono, C.; Come, C.E.; Witztum, J.L.; Maguire, G.F.; Connelly, P.W.; Carroll, M.; Lichtman, A.H. Influence of C3 deficiency on atherosclerosis. Circulation 2002, 105, 3025–3031. [Google Scholar] [CrossRef] [Green Version]
- Ahnach, M.; Zbiri, S.; Nejjari, S.; Ousti, F.; Elkettani, C. C-reactive protein as an early predictor of COVID-19 severity. J. Med. Biochem. 2020, 39, 500–550. [Google Scholar] [CrossRef]
- Han, H.; Ma, Q.; Li, C.; Liu, R.; Zhao, L.; Wang, W.; Zhang, P.; Liu, X.; Gao, G.; Liu, F.; et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg. Microbes Infect. 2020, 9, 1123–1130. [Google Scholar] [CrossRef]
- Tirelli, C.; De Amici, M.; Albrici, C.; Mira, S.; Nalesso, G.; Re, B.; Corsico, A.G.; Mondoni, M.; Centanni, S. Exploring the Role of Immune System and Inflammatory Cytokines in SARS-CoV-2 Induced Lung Disease: A Narrative Review. Biology 2023, 12, 177. [Google Scholar] [CrossRef] [PubMed]
- Lowery, S.A.; Sariol, A.; Perlman, S. Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19. Cell Host Microbe 2021, 29, 1052–1062. [Google Scholar] [CrossRef]
- Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020, 395, 1054–1062, Erratum in Lancet 2020, 395, 1038. [Google Scholar] [CrossRef]
- Del Valle, D.M.; Kim-Schulze, S.; Huang, H.H.; Beckmann, N.D.; Nirenberg, S.; Wang, B.; Lavin, Y.; Swartz, T.H.; Madduri, D.; Stock, A.; et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 2020, 26, 1636–1643. [Google Scholar] [CrossRef]
- Vorobjeva, N.V.; Chernyak, B.V. NETosis: Molecular mechanisms, role in physiology and pathology. Biochemistry 2020, 85, 1178–1190. [Google Scholar] [CrossRef] [PubMed]
- González-Jiménez, P.; Méndez, R.; Latorre, A.; Piqueras, M.; Balaguer-Cartagena, M.N.; Moscardó, A.; Alonso, R.; Hervás, D.; Reyes, S.; Menéndez, R. Neutrophil Extracellular Traps and Platelet Activation for Identifying Severe Episodes and Clinical Trajectories in COVID-19. Int. J. Mol. Sci. 2023, 24, 6690. [Google Scholar] [CrossRef]
- Liao, Y.C.; Liang, W.G.; Chen, F.W.; Hsu, J.H.; Yang, J.J.; Chang, M.S. IL-19 induces production of IL-6 and TNF-alpha and results in cell apoptosis through TNF-alpha. J. Immunol. 2002, 169, 4288–4297. [Google Scholar] [CrossRef] [Green Version]
- Xu, H.; Zhong, L.; Deng, J.; Peng, J.; Dan, H.; Zeng, X.; Li, T.; Chen, Q. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int. J. Oral Sci. 2020, 12, 8. [Google Scholar] [CrossRef] [Green Version]
- Helal, M.A.; Shouman, S.; Abdelwaly, A.; Elmehrath, A.O.; Essawy, M.; Sayed, S.M.; Saleh, A.H.; El-Badri, N. Molecular basis of the potential interaction of SARS-CoV-2 spike protein to CD147 in COVID-19 associated-lymphopenia. J. Biomol. Struct. Dyn. 2022, 40, 1109–1119. [Google Scholar] [CrossRef] [PubMed]
- Tan, L.; Wang, Q.; Zhang, D.; Ding, J.; Huang, Q.; Tang, Y.Q.; Wang, Q.; Miao, H. Lymphopenia predicts disease severity of COVID-19: A descriptive and predictive study. Signal Transduct. Target. Ther. 2020, 5, 33. [Google Scholar] [CrossRef] [PubMed]
- Qin, C.; Zhou, L.; Hu, Z.; Zhang, S.; Yang, S.; Tao, Y.; Xie, C.; Ma, K.; Shang, K.; Wang, W.; et al. Dysregulation of Immune Response in Patients with Coronavirus 2019 (COVID-19) in Wuhan, China. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2020, 71, 762–768. [Google Scholar] [CrossRef]
- Petrie, H.T.; Klassen, L.W.; Kay, H.D. Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes. J. Immunol. 1985, 134, 230–234. [Google Scholar] [CrossRef]
- El-Hag, A.; Clark, R.A. Immunosuppression by activated human neutrophils. Dependence on the myeloperoxidase system. J. Immunol. 1987, 139, 2406–2413. [Google Scholar] [CrossRef]
- Cataudella, E.; Giraffa, C.M.; Di Marca, S.; Pulvirenti, A.; Alaimo, S.; Pisano, M.; Terranova, V.; Corriere, T.; Ronsisvalle, M.L.; Di Quattro, R.; et al. Neutrophil-To-Lymphocyte Ratio: An Emerging Marker Predicting Prognosis in Elderly Adults with Community-Acquired Pneumonia. J. Am. Geriatr. Soc. 2017, 65, 1796–1801. [Google Scholar] [CrossRef]
- Paliogiannis, P.; Fois, A.G.; Sotgia, S.; Mangoni, A.A.; Zinellu, E.; Pirina, P.; Negri, S.; Carru, C.; Zinellu, A. Neutrophil to lymphocyte ratio and clinical outcomes in COPD: Recent evidence and future perspectives. Eur. Respir. Rev. Off. J. Eur. Respir. Soc. 2018, 27, 170113. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, S.; Wang, X.; She, F.; Zhang, W.; Liu, H.; Zhao, X. Effects of Neutrophil-to-Lymphocyte Ratio Combined with Interleukin-6 in Predicting 28-Day Mortality in Patients with Sepsis. Front. Immunol. 2021, 12, 639735. [Google Scholar] [CrossRef]
- Cupp, M.A.; Cariolou, M.; Tzoulaki, I.; Aune, D.; Evangelou, E.; Berlanga-Taylor, A.J. Neutrophil to lymphocyte ratio and cancer prognosis: An umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med. 2020, 18, 360. [Google Scholar] [CrossRef]
- Afari, M.E.; Bhat, T. Neutrophil to lymphocyte ratio (NLR) and cardiovascular diseases: An update. Expert Rev. Cardiovasc. Ther. 2016, 14, 573–577. [Google Scholar] [CrossRef]
- Buonacera, A.; Stancanelli, B.; Colaci, M.; Malatino, L. Neutrophil to Lymphocyte Ratio: An Emerging Marker of the Relationships between the Immune System and Diseases. Int. J. Mol. Sci. 2022, 23, 3636. [Google Scholar] [CrossRef] [PubMed]
- Yang, A.P.; Liu, J.P.; Tao, W.Q.; Li, H.M. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int. Immunopharmacol. 2020, 84, 106504. [Google Scholar] [CrossRef] [PubMed]
- Poggiali, E.; Zaino, D.; Immovilli, P.; Rovero, L.; Losi, G.; Dacrema, A.; Nuccetelli, M.; Vadacca, G.B.; Guidetti, D.; Vercelli, A.; et al. Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in COVID-19 patients. Clin. Chim. Acta 2020, 509, 135–138. [Google Scholar] [CrossRef]
- Herold, T.; Jurinovic, V.; Arnreich, C.; Lipworth, B.J.; Hellmuth, J.C.; von Bergwelt-Baildon, M.; Klein, M.; Weinberger, T. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J. Allergy Clin. Immunol. 2020, 146, 128–136.e4. [Google Scholar] [CrossRef]
- Mueller, A.A.; Tamura, T.; Crowley, C.P.; DeGrado, J.R.; Haider, H.; Jezmir, J.L.; Keras, G.; Penn, E.H.; Massaro, A.F.; Kim, E.Y. Inflammatory Biomarker Trends Predict Respiratory Decline in COVID-19 Patients. Cell Rep. Med. 2020, 1, 100144. [Google Scholar] [CrossRef]
- Besutti, G.; Giorgi Rossi, P.; Ottone, M.; Spaggiari, L.; Canovi, S.; Monelli, F.; Bonelli, E.; Fasano, T.; Sverzellati, N.; Caruso, A.; et al. Inflammatory burden and persistent CT lung abnormalities in COVID-19 patients. Sci. Rep. 2022, 12, 4270. [Google Scholar] [CrossRef] [PubMed]
- Palanidurai, S.; Phua, J.; Chan, Y.H.; Mukhopadhyay, A. P/FP ratio: Incorporation of PEEP into the PaO2/FiO2 ratio for prognostication and classification of acute respiratory distress syndrome. Ann. Intensive Care 2021, 11, 124. [Google Scholar] [CrossRef] [PubMed]
- Soliman, O.M.; Moeen, S.M.; Abbas, Y.A.; Kamel, E.Z. The impact of dexamethasone versus methylprednisolone upon neutrophil/lymphocyte ratio in COVID-19 patients admitted to ICU and its implication upon mortality. Egypt. J. Anaesth. 2022, 38, 78–84. [Google Scholar] [CrossRef]
Low Flow Oxygen Therapy | High Flow Oxygen Therapy | NIMV | |||||||
---|---|---|---|---|---|---|---|---|---|
Nasal Cannula | Venturi Mask | Venturi Mask | HFNC | C-PAP | NIV | ||||
1–3 L/min (FiO2 = 0.24–0.32) | 4–6 L/min (FiO2 = 0.36–0.44) | 4–8 L/min (FiO2 = 0.24–0.35) | 10–12 L/min (FiO2 = 0.40–0.60) | FiO2 = 0.40–0.60 | FiO2 ≤ 0.40 | FiO2 = 0.41–0.50 | FiO2 = 0.51–0.60 | FiO2 = 0.50–1.00 | |
Patients, n | 51 | 46 | 101 | 67 | 115 | 29 | 89 | 54 | 52 |
TOTAL n = 764 | SURVIVORS n = 534 | ICU ADMITTED n = 106 | DECEASED n = 124 | p | |
---|---|---|---|---|---|
Age, Years | 74 (72–75) | 71 (69–73) | 71 (67–73) | 85 (84–86) | <0.000001 |
Male Sex, n (%) | 412 (54.1) | 282 (68.2) | 69 (16.7) | 61 (14.8) | 0.019 |
Lymph, 109/L | 800 (718–800) | 900 (800–900) | 581 (506–820) | 600 (500–671) | <0.000001 |
ANC, 109/L | 6500 (6200–6800) | 5900 (5600–6300) | 7500 (6760–8927) | 9000 (7500–9039) | <0.000001 |
P/F Ratio | 206 (198–224) | 258 (241–272) | 171(121–133) | 128 (117–146) | <0.000001 |
NLR T0 | 8.18 (7.7–8.9) | 6.7 (6.2–7.3) | 13.2 (11.1–15.8) | 15.5 (13.6–18.6) | <0.000001 |
NLR T1 | 8.7 (7.8–9.7) | 7 (6.1–7.8) | 13.5 (11–16) | 23 (17.8–31.3) | <0.000001 |
NLR T2 | 8.9 (8.6–10.5) | 5.2 (4.5–5.3) | 13.5 (12.4–22.4) | 33 (22.6–41.7) | <0.000001 |
CRP T0, mg/dL | 9.4 (8.4–10.6) | 7.7 (6.2–8.7) | 22 (12.8–73.8) | 13 (9.3–15.5) | <0.000001 |
CRP T1, mg/dL | 3.3 (2.5–4.5) | 1.9 (1.4–2.4) | 16.2 (8.5–25) | 9.7 (6.9–11) | <0.000001 |
CRP T2, mg/dL | 4.9 (3–6.6) | 1.5 (1.3–2.2) | 52.7 (22.4–101) | 10 (8.1–16.8) | <0.000001 |
Length of Stay, Days | 9 (8–10) | 10 (10–11) | 4 (3–5) | 8 (7–9) | <0.000001 |
Comorbidities | |||||
Hypertension n (%) | 457 (62.5) | 306 (57) | 68 (64) | 83 (66) | 0.09 |
Diabetes, n (%) | 334 (43.9) | 221 (41) | 47 (44) | 66 (53) | 0.06 |
CKD, n (%) | 166 (21.7) | 105 (19) | 30 (28) | 31 (25) | 0.082 |
COPD, n (%) | 107 (13.8) | 82 (15) | 11 (10) | 14 (11) | 0.252 |
CV Disease, n (%) | 297 (25.7) | 198 (37) | 47 (44) | 52 (41) | 0.279 |
Dependent Variable P/F Ratio | WHOLE POPULATION | SURVIVORS | ICU ADMISSION | DECEASED | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
β | r | p | β | r | p | β | r | p | β | r | p | |
NLR | −1.91 | −0.22 | <0.0001 | −1.68 | −0.13 | 0.002 | −0.35 | −0.007 | 0.438 | −0.84 | −2.2 | 0.023 |
CRP | −0.5 | −0.27 | <0.0001 | −0.65 | −0.24 | <0.0001 | −0.19 | −0.23 | 0.015 | −0.15 | −1.5 | 0.134 |
DEPENDENT VARIABLE: DECEASE | ||||
---|---|---|---|---|
HR Univariable | p | HR Multivariable | p | |
NLR | 1.05 (2.01 *) [1.0406–1.0709] | <0.0001 | 1.04 (1.77 *) [1.0295–1.0618] | <0.0001 |
CRP | 1.002 [0.9996–1.0058] | 0.0879 | 1.002 (1.001 *) [0.9994–1.0063] | 0.1081 |
DEPENDENT VARIABLE: ICU ADMISSION | ||||
HR Univariable | p | HR Multivariable | p | |
NLR | 1.02 (1.4 *) [1.0127–1.0390] | 0.0001 | 1.02 (1.39 *) [1.0117–1.0419] | 0.002 |
CRP | 2.66 [2.4315–3.1368] | <0.0001 | 2.4 (1.7 *) [1.922–2.615] | <0.0001 |
95% Confidence Interval | |||||||
---|---|---|---|---|---|---|---|
Effect | Estimate | SE * | Lower | Upper | Z ** | p | % Mediation |
Indirect | −0.035 | 0.174 | −0.940 | −0.251 | −3.19 | 0.001 | 16.3 |
Direct | −2.849 | 0.640 | −4.153 | −1.583 | −4.45 | <0.001 | 83.7 |
Total | −3.404 | 0.672 | −4.678 | −2.112 | −5.07 | <0.001 | 100.0 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Regolo, M.; Sorce, A.; Vaccaro, M.; Colaci, M.; Stancanelli, B.; Natoli, G.; Motta, M.; Isaia, I.; Castelletti, F.; Giangreco, F.; et al. Assessing Humoral Immuno-Inflammatory Pathways Associated with Respiratory Failure in COVID-19 Patients. J. Clin. Med. 2023, 12, 4057. https://0-doi-org.brum.beds.ac.uk/10.3390/jcm12124057
Regolo M, Sorce A, Vaccaro M, Colaci M, Stancanelli B, Natoli G, Motta M, Isaia I, Castelletti F, Giangreco F, et al. Assessing Humoral Immuno-Inflammatory Pathways Associated with Respiratory Failure in COVID-19 Patients. Journal of Clinical Medicine. 2023; 12(12):4057. https://0-doi-org.brum.beds.ac.uk/10.3390/jcm12124057
Chicago/Turabian StyleRegolo, Matteo, Alessandra Sorce, Mauro Vaccaro, Michele Colaci, Benedetta Stancanelli, Giuseppe Natoli, Massimo Motta, Ivan Isaia, Federica Castelletti, Federica Giangreco, and et al. 2023. "Assessing Humoral Immuno-Inflammatory Pathways Associated with Respiratory Failure in COVID-19 Patients" Journal of Clinical Medicine 12, no. 12: 4057. https://0-doi-org.brum.beds.ac.uk/10.3390/jcm12124057